Group 1 - The first China Comprehensive Bonded Zone Development International Forum was held in Haikou, focusing on "Innovation, Cooperation, and High-Quality Development" under the global economic and trade changes [1] - The representative from the Qianhai Management Bureau highlighted three major advantages of the Qianhai Comprehensive Bonded Zone: geographical advantage, strategic platform advantage, and industrial chain advantage [1][2] - Qianhai Comprehensive Bonded Zone has a small closure area of only 2.28 square kilometers, yet it is projected to achieve an import and export total of 375.25 billion yuan in 2024, reflecting a growth of 49.9% [2] Group 2 - The Qianhai Comprehensive Bonded Zone ranked third among 161 bonded zones in China in terms of import and export scale for the first eight months of 2025, with a value of 247.32 billion yuan [2] - The zone is evolving from a single "policy highland" to a diversified "open ecosystem," enhancing logistics and supply chain capabilities while promoting cross-border trade and innovation [2] - Key themes for sustainable development in the comprehensive bonded zone include openness, integration, and innovation, with a focus on institutional innovation and collaboration [2]

Core Viewpoint - The company is convening its third extraordinary general meeting of shareholders in 2025 to discuss and vote on key proposals, including a cooperation framework agreement with Dongfang Yanmei (Chengdu) Biotechnology Co., Ltd. and adjustments to daily related party transactions [1][12]. Meeting Procedures - Shareholders and their representatives must arrive 30 minutes before the meeting to sign in and present identification [2]. - The meeting will follow a structured agenda, including the announcement of the number of shareholders present and their voting rights [7]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the conduct of discussions and questions [3][4]. Voting and Decision-Making - Voting will be conducted through both on-site and online methods, with results announced at the end of the meeting [5][6]. - Shareholders must express their opinions on the proposals as either in favor, against, or abstaining, and must sign their ballots [4][5]. Proposed Agreements - The company plans to sign a cooperation framework agreement with Dongfang Yanmei, which includes a procurement cap of CNY 10 million for 2025, CNY 20 million for 2026, and CNY 20 million for 2027 [12][13]. - The agreement aims to leverage both parties' resources for mutual benefit in the pharmaceutical research and development sector [12][17]. Related Party Transactions - The company is adjusting its expected daily related party transaction limits based on operational needs and market pricing [11][12]. - The adjustments are necessary for maintaining normal business operations and are expected to enhance market competitiveness and operational efficiency [12][17]. Financial and Operational Context - The company has established a stable relationship with its related parties, ensuring that these transactions do not adversely affect its independence or financial health [12][17]. - The cooperation with Dongfang Yanmei is positioned as a strategic move to enhance the company's capabilities in clinical trials and related services [12][17].